Organigram Global Inc.

Capital structure and liquidity metrics are unavailable as the financial snapshot is missing. The market price is recorded at $0.939. Without balance sheet data, debt levels, cash positions, and current ratios cannot be assessed.

Profitability and return metrics are absent from the valuation snapshot. Analyst estimates indicate a mean EPS of 0.13 CAD, contrasting with a last actual EPS of -0.22 CAD. Mean revenue estimates stand at 339,569,000 CAD, while last actual revenue was 259,183,000 CAD. Mean EBIT is estimated at -15,141,330 CAD.

Segment and geographic revenue mix data is not provided in the input. The company’s classification as a pharmaceuticals entity suggests potential exposure to regulated markets, but specific concentration risks cannot be quantified without segment disclosures.

Growth trajectory analysis is limited by the absence of historical period data. However, the discrepancy between mean revenue estimates (339,569,000 CAD) and last actual revenue (259,183,000 CAD) suggests anticipated growth or correction in analyst expectations. The negative actual EPS of -0.22 CAD indicates recent unprofitability.

Risk assessment is constrained by missing financial data. Key flags indicate that risk could not be assessed due to the absence of a financial snapshot, source documents, or observations. Liquidity and dilution risks are marked as unknown.

Recent events highlight a critical listing compliance issue. The stock closed below $1.00 for 20 consecutive trading days, approaching the NASDAQ minimum-bid deficiency threshold of 30 days under Rule 5550(a)(2) and Rule 5810(c)(3)(A). The last close was $0.9387. ESG scores show a total score of 38.84, with Environment at 11.72 and Social at 26.88.